Influenza vaccines that better target the influenza surface protein called neuraminidase (NA) could offer broad protection against various influenza virus strains and lessen the severity of illness, according to new research published in Cell.
Current seasonal influenza vaccines mainly target a different, more abundant influenza surface protein called hemagglutinin (HA). However, because influenza vaccines offer varying and sometimes limited protection, scientists are exploring ways to improve vaccine effectiveness. The new research builds on previous studies of NA and was conducted by a team of scientists including investigators from the Centers of Excellence for Influenza Research and Surveillance (CEIRS)program, which is organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Investigators analyzed blood samples from people vaccinated against influenza and people diagnosed with either the 2009 H1N1 influenza virus or H3N2 influenza viruses. The volunteers were recruited for this study or had taken part in prior influenza research studies. The analyses indicate that influenza vaccines rarely induce NA-reactive antibodies, whereas natural influenza infection induces these types of antibodies at least as often as they induce HA-reactive antibodies. Additional studies in mice reinforced the human data, indicating that current influenza vaccines do not induce NA-reactive antibodies efficiently.
Additional laboratory experiments show that the NA-reactive antibodies induced during natural influenza infection are broadly reactive, meaning they could potentially protect against diverse strains of influenza. To test this theory, scientists isolated NA-reactive monoclonal antibodies from the H3N2 and H1N1 influenza patients (N2-reactive antibodies and N1-reactive antibodies, respectively). They administered 13 N2-reactive antibodies to mice and subsequently infected the mice with a different H3N2 virus strain. Eleven of the 13 N2-reactive antibodies partially or fully protected the mice. They also administered eight N1-reactive antibodies to mice and subsequently infected the mice with a similar H1N1 virus strain or an H5N1-like virus strain. Four of the eight antibodies completely protected the mice against both virus strains.
The authors note that the findings suggest that influenza vaccines should be optimized to better target NA for broad protection against diverse influenza strains. In this regard, NIAID is supporting research to characterize NA responses in infected and vaccinated individuals and to determine the mechanism of action of NA protection. NIAID also supports “NAction!” a CEIRS working group that identifies knowledge gaps in our understanding of NA and sets NA research priorities for improved influenza vaccines. These efforts contribute to NIAID’s larger plan to develop a universal influenza vaccine—a vaccine that can durably protect all age groups against multiple influenza virus strains.
The Latest on: Influenza
via Google News
The Latest on: Influenza
- The Worldwide Influenza Diagnostics Industry is Expected to Reach $1.1 Billion by 2026 - ResearchAndMarkets.comon October 11, 2021 at 9:02 am
Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular (PCR, INAAT- NASBAT, TMABAS), End User (Diagnostic Laboratories, Hospitals, Clinics), Region-Global Forecast to 2026" report has ...
- U.S. Influenza Diagnostics Market Research Analysis, and Future Innovations | Grand View Research, Inc.on October 11, 2021 at 7:05 am
According to a new report published by Grand View Research, influenza is a contagious disease therefore, there is an easy transmission of the disease ...
- Prior immunity to influenza, not SARS-CoV-2, prevents severe disease and mortalityon October 11, 2021 at 3:07 am
Researchers from the Israel Institute of Biological Research delineated the interplay between IAV and SARS CoV-2 infections.
- Health officials warn of ‘triple threat’ this fall: RSV, influenza and COVID-19on October 10, 2021 at 7:07 pm
Once again, flu season is upon us. Each year, it can vary, but usually lasts from October through May. This fall, it’s especially important to get vaccinated since flu is not the only ...
- Severe influenza outbreak expected in the United States after relaxation of COVID control measureson October 9, 2021 at 8:02 pm
New research warns that the United States could experience a severe influenza outbreak after public health measures like face masks and social distancing are lifted.
- COVID Or Flu? New Test Can Detect Both Coronavirus And Influenza Viruson October 8, 2021 at 9:11 pm
With similar symptoms like fever, tiredness, cough, and shortness of breath... doctors around the Denver metro area will have another tool to determine if patients are sick with COVID-19 or influenza.
- Influenza hemagglutinin attachment to target cells: ‘birds do it, we do it…’on October 8, 2021 at 5:56 pm
Influenza A viruses have been much in the news lately, and rightly so. This divergent group of viruses has caused occasional and unpredictable pandemics, some with horrific consequences, and also ...
- US Health Officials Urge Vaccination Amid Concerns About Influenza Resurgence During Ongoing Pandemicon October 7, 2021 at 6:57 am
"While we do not know what flu activity will be like this fall—I urge everyone age 6 months and older to get vaccinated. If you are unsure about getting a flu vaccine, please take the time to get the ...
- Don't forget about the return of influenzaon October 6, 2021 at 10:32 pm
COVID-19 has been the hot topic for the past year and a half, monopolizing TV news programs and documentaries. However, we cannot forget about the infectious disease that returns every ...
via Bing News